Month: August 2021

FREMONT, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) — Enovix Corporation (“Enovix”) (Nasdaq: ENVX, ENVXW), the leader in the design and manufacture of next generation 3D Silicon™ Lithium-ion batteries, today posted to its website at https://ir.enovix.com a quarterly shareholder letter containing the financial results for the second quarter of 2021, ending June 30. The shareholder letter provides a business update that details progress made in the quarter along several key areas including technology, production and commercialization. “We enter the second half of 2021 focused on executing our plan to deliver batteries to category-leading customers with industry-leading energy densities,” said Harrold Rust, President, Chief Executive Officer and Co-Founder of Enovix. “We have made tremendous progress in equipping our first advanced production...

UBX1325 demonstrates favorable tolerability in Phase 1 safety study and improvement in visual acuity and central subfield thickness in majority of patients with diabetic macular edema (DME) and wet age-related macular degeneration (AMD) Results from Phase 1 study of UBX1325 in additional patients with wet AMD expected by end of year UBX1325 Phase 2a proof-of-concept study enrolling patients with DME; data expected first half of 2022 SOUTH SAN FRANCISCO, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the second quarter ended June 30, 2021. “This quarter has been exciting and productive, marked by the compelling data from the Phase 1 study of UBX1325. In addition...

Harrold Rust, President and Chief Executive Officer of EnovixHarrold Rust, President and Chief Executive Officer of Enovix at the Enovix factory in Fremont, CaliforniaFREMONT, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) — Enovix Corporation (“Enovix”) (Nasdaq: ENVX, ENVXW), the leader in the design and manufacture of next generation 3D Silicon™ Lithium-ion batteries, announced today it achieved a key manufacturing facility milestone, completing equipment installation of its first U.S.-based advanced battery production line. Enovix also announced it signed a Master Purchase Agreement and a Cooperation Agreement with a California-based technology leader focused initially on the wearable device space. Based on the terms of the agreements, Enovix will receive a manufacturing capacity reservation fee and pre-payments totaling...

INDIANAPOLIS, Aug. 10, 2021 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announced the completion of enrollment and initial dosing of the 25-patient safety and dosimetry lead-in of the Company’s Phase 3 SPLASH study evaluating PNT2002 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). “Patient enrollment and initial dosing was completed significantly ahead of schedule,” said Dr. Joe McCann, Chief Executive Officer of POINT Biopharma. “I am incredibly proud of our team for this achievement, especially considering it occurred during an unprecedented global pandemic. I believe the speed of enrollment further highlights the caliber of POINT’s team, as well as the unmet need of...

Q2 2021 End of Period Subscribers of 4.9 millionQ2 2021 End of Period Digital Subscribers up 6% year-over-year to an all-time Q2-end highQ2 2021 Revenues of $311 millionQ2 2021 Gross Margin of 60%; excluding one-time charges, Q2 2021 adjusted gross margin increased 100 basis points year-over-year to 61%FY 2021 Guidance: Revenues approaching $1.3 billion and GAAP EPS in the range of $1.10 to $1.25, which incorporates an approximately $0.53 aggregate negative impact from the early extinguishment of debt and estimated restructuring charges in 2021NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) — WW International, Inc. (NASDAQ: WW) today announced its results for the second quarter of fiscal 2021. “We ended the quarter with 4.9 million subscribers, including 4.1 million Digital subscribers — an all-time second quarter-end...

SANTA BARBARA, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) — Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company exclusively focused on plastic surgery, today announced its financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Financial HighlightsRecord Breast Products revenue of $20.1 million, a 116% year-over-year increase10% sequential growth over the first quarter of 2021 80% growth over the second quarter of 2019Cash of $82.4 million as of June 30, 2021, a $2 million increase from March 31, 2021 Updated full year 2021 guidance for revenues expected to range from $74 to $78 million, representing 35%-42% growth year-over-yearRecent Business HighlightsAdded more than 300 accounts in the second quarter, achieving a new record base of more than 2,400 accounts Generated...

Top-line data readouts expected from four Phase 2 trials of oral AMT-101, consistent with previous guidanceCombination trial of AMT-101 with anti-TNFα in moderate-to-severe ulcerative colitis (UC) patients in the fourth quarter of 2021; Monotherapy trial in pouchitis, combination trial with anti-TNFα in rheumatoid arthritis (RA) and monotherapy trial in UC in 2022Phase 1 enrollment on-going for second product candidate, oral AMT-126, with top-line data readout expected in 2022 Strengthened balance sheet with successful follow-on offering in April with net proceeds of approximately $113 million; As of June 30, 2021, cash, cash equivalents, and investments of approximately $200 million Virtual R&D Day planned for October 15, 2021, to discuss platform technology, clinical programs and research activities SOUTH SAN FRANCISCO, Calif.,...

CRN04894 Phase 1 Study Progressing to Multiple Ascending Dose Cohorts Management Hosting Webcast and Conference Call Today to Discuss Findings at 4:30 p.m. Eastern Time SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced positive preliminary findings from the single ascending dose (SAD) portion of a first-in-human Phase 1 clinical study with CRN04894 demonstrating pharmacologic proof-of-concept for this first-in-class, investigational, oral, nonpeptide adrenocorticotropic hormone (ACTH) antagonist that is being developed for the treatment of conditions of ACTH excess, including Cushing’s disease...

– Reports Record Second Quarter Revenue Increased 38% Year-Over-Year to $59.7 million – – System Solutions Revenue Increased 62% to $51.2 million – – Second Quarter Gross Profit Margin Expands More Than 500 bps Year-Over-Year – – Backlog and Awarded Orders at June 30, 2021 Up 63% Versus Last Year – – Reaffirms 2021 Outlook – PORTLAND, Tenn., Aug. 10, 2021 (GLOBE NEWSWIRE) — Shoals Technologies Group, Inc. (“Shoals” or the “Company”) (Nasdaq: SHLS), a leading provider of electrical balance of system (“EBOS”) solutions for solar, battery storage and electric vehicle charging infrastructure, today announced results for its second quarter ended June 30, 2021. “Shoals delivered another record quarter, with revenue growth accelerating to 38% year-over-year and gross margin improving over 500 basis points. System solutions grew 62% year-over-year...

Second Quarter 2021 Revenue Grew 44% Year-Over-Year to $49.9 Million LOS ANGELES, Aug. 10, 2021 (GLOBE NEWSWIRE) — PLBY Group, Inc. (NASDAQ: PLBY) (“PLBY Group” or the “Company”), a leading pleasure and leisure lifestyle company and owner of Playboy, one of the most recognizable and iconic brands in the world, today provided financial results for the second quarter ended June 30, 2021. Ben Kohn, Chief Executive Officer of PLBY Group, stated, “We are pleased to report another successful quarter that demonstrates the powerful combination of our growing direct-to-consumer business, an optimized licensing operation and scalable digital offerings. On the direct-to-consumer side, we saw great traction on Playboy.com with expanded merchandise offerings and strategic influencer marketing. In addition, the second quarter marked continued...